Ask The Board

  1. The Overall Complexity Of Biopharma Operations Is Increasing. How Do You Strategize To Meet Current And Future Needs In The Most Efficient (e.g., Cost) Manner Possible? 12/30/2019

    See the answer from Jacks Lee, a global pharmaceutical executive with 25+ years of experiences in vaccines, biopharmaceuticals, and small molecule pharmaceuticals.

  2. Have You Had To Retire Or Remove A Director From Your Board? If So, How Did You Approach It? 12/30/2019

    See the answer from Thomas Wiggans, chairman and CEO of Dermira, Inc.

  3. When You Have Investors/VCs On Your Board, How Do You Help Them Keep Their Director Hat On Vs. Their Investor Hat When Making Decisions? 12/30/2019

    See the answer from Fred Hassan, managing director at Warburg Pincus and former chairman of Bausch & Lomb.

  4. Overall, What Is Your Biggest Biopharma Industry-Related Concern? 11/27/2019

    See the answer from Julia Owens, Ph.D., president, CEO, and co-founder of Millendo Therapeutics.

  5. What Nonbiopharma Companies Could Have The Biggest Impact On The Industry In 2020? 11/27/2019

    See the answer from Al Altomari, chairman, and CEO of Agile Therapeutics.

  6. What Nonbiopharma Company Will Have The Biggest Impact On The Industry Over The Next Five Years? 11/27/2019

    See the answer from Martin Lehr, CEO and cofounder at Context Therapeutics.

  7. What Advice Do You Have For Preventing Fraud Schemes In Large Phase 3 Studies? 11/1/2019

    See the answer from Dr. Axel Hoos, SVP, R&D governance chair, and therapeutic area (TA) head for oncology at GSK.

  8. What Advice Do You Have For Executives Considering Ex-Pat Opportunities In South American Countries? 11/1/2019

    See the answer from Raúl Diaz, who directs MSD Animal Health Large Molecules Biopharm Operations in Montes Claros, Brazil.

  9. What Advice Do You Have For An Executive Weighing An Exit From A Company For Which They Are A Leader And A Board Member? 11/1/2019

    See the answer from Rich Daly, COO of BeyondSpring, who has more than 25 years of biopharmaceutical industry leadership experience.

  10. What Is The Most Ridiculous Justification You Have Ever Heard To Rationalize An Inefficient /Expensive Capital Structure? 10/1/2019

    See the answer from Allan Shaw, a four-time public company CFO who has served on five public boards.